Vasanti S Malik1. 1. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: It is widely accepted that sugar sweetened beverages (SSB) are implicated in weight gain and adverse cardiometabolic heath. To make informed recommendations about SSB, new evidence needs to be considered against existing literature. The present review will provide an update on the epidemiological and trial evidence linking intake of SSB to cardiometabolic outcomes. RECENT FINDINGS: The weight of the evidence from prospective cohort studies supports a strong positive association between intake of SSB and weight gain and risk type 2 diabetes (T2D) and coronary heart disease (CHD) that is independent of adiposity. Associations with stroke are less clear and suggestive of greater risk in women than men. Findings from short-term trials of SSB and markers of cardiometabolic risk including lipids, glucose, blood pressure, and inflammatory cytokines provide mechanistic support for associations with T2D and CHD. Putative underlying mechanisms include adverse glycemic effects and increased hepatic metabolism of fructose. SUMMARY: Conclusive evidence from epidemiological studies and trials on markers of cardiometabolic risk support an etiologic role of SSB in relation to weight gain and risk of T2D and CHD that is independent of weight. Continued efforts to reduce intake of SSB should be encouraged to improve the cardiometabolic health of individuals and populations.
PURPOSE OF REVIEW: It is widely accepted that sugar sweetened beverages (SSB) are implicated in weight gain and adverse cardiometabolic heath. To make informed recommendations about SSB, new evidence needs to be considered against existing literature. The present review will provide an update on the epidemiological and trial evidence linking intake of SSB to cardiometabolic outcomes. RECENT FINDINGS: The weight of the evidence from prospective cohort studies supports a strong positive association between intake of SSB and weight gain and risk type 2 diabetes (T2D) and coronary heart disease (CHD) that is independent of adiposity. Associations with stroke are less clear and suggestive of greater risk in women than men. Findings from short-term trials of SSB and markers of cardiometabolic risk including lipids, glucose, blood pressure, and inflammatory cytokines provide mechanistic support for associations with T2D and CHD. Putative underlying mechanisms include adverse glycemic effects and increased hepatic metabolism of fructose. SUMMARY: Conclusive evidence from epidemiological studies and trials on markers of cardiometabolic risk support an etiologic role of SSB in relation to weight gain and risk of T2D and CHD that is independent of weight. Continued efforts to reduce intake of SSB should be encouraged to improve the cardiometabolic health of individuals and populations.
Authors: Patrícia Molz; Walter A Molz; Danieli R Dallemole; Augusto F Weber; Mirian Salvador; Daniel Prá; Silvia I R Franke Journal: Biol Trace Elem Res Date: 2020-07-25 Impact factor: 3.738
Authors: Allison R Webel; Shirley M Moore; Chris T Longenecker; Jackson Currie; Christine Horvat Davey; Joseph Perazzo; Abdus Sattar; Richard A Josephson Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Lu Jia; Haiwen Lu; Jing Wu; Xuemei Wang; Wenrui Wang; Maolin Du; Peiyu Wang; Sha Du; Yuenan Su; Nan Zhang Journal: BMC Public Health Date: 2020-07-25 Impact factor: 3.295
Authors: Danielle E Haslam; Nicola M McKeown; Mark A Herman; Alice H Lichtenstein; Hassan S Dashti Journal: Front Endocrinol (Lausanne) Date: 2018-01-08 Impact factor: 5.555
Authors: Danielle E Haslam; Gina M Peloso; Mark A Herman; Josée Dupuis; Alice H Lichtenstein; Caren E Smith; Nicola M McKeown Journal: J Am Heart Assoc Date: 2020-02-26 Impact factor: 5.501